The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Open accessAbstract
BACKGROUND: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survival. RESULTS: A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at high risk for progression, and 70% had stage IIIC or IV ovarian cancer. Progression-free survival (restricted mean) at 36 months was 20.3 months with standard therapy, as compared with 21.8 months with standard therapy plus bevacizumab (hazard ratio for progression or death with bevacizumab added, 0.81; 95% confidence interval, 0.70 to 0.94; P=0.004 by the log-rank test). Nonproportional hazards were detected (i.e., the treatment effect was not consistent over time on the hazard function scale) (P<0.001), with a maximum effect at 12 months, coinciding with the end of planned bevacizumab treatment and diminishing by 24 months. Bevacizumab was associated with more toxic effects (most often hypertension of grade 2 or higher) (18%, vs. 2% with chemotherapy alone). In the updated analyses, progression-free survival (restricted mean) at 42 months was 22.4 months without bevacizumab versus 24.1 months with bevacizumab (P=0.04 by log-rank test); in patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months with standard therapy alone and 18.1 months with bevacizumab added, with respective median overall survival of 28.8 and 36.6 months. CONCLUSIONS: Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Royston, P., & Parmar, M. K. B. (2002) · Statistics in Medicine · doi:10.1002/sim.1203 · Cited by 1,529
Self-citationAlberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Anti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Cited by
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Self-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationJayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Self-citationPujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Self-citationKehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationSteeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Self-citationColombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citationGarcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Self-citationVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Self-citationAntiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
“4 [117]”
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S. P., & Kaye, S. B. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3432 · Cited by 562
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Self-citationKuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Moore, K. N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00306 · Cited by 414
Self-citationColombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Self-citationFagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chiantera, V., Costantini, B., Margariti, P. A., Gueli Alletti, S., Cosentino, F., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.017 · Cited by 395
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Self-citationHornburg, M., Desbois, M., Lu, S., Guan, Y., Lo, A. A., Kaufman, S., Elrod, A., Lotstein, A., DesRochers, T. M., Munoz-Rodriguez, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.004 · Cited by 383
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
Can advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
The forefront of ovarian cancer therapy: update on PARP inhibitors
Mirza, M. R., Coleman, R. L., González-Martín, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.004 · Cited by 365
Self-citationRay-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.005 · Cited by 365
Self-citationBanerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Ledermann, J. A., Canevari, S., & Thigpen, T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv250 · Cited by 347
Self-citationTreatment of recurrent ovarian cancer
Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 338
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Coleman, R. L., Spirtos, N. M., Enserro, D., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Kim, J.-W., Park, S.-Y., Kim, B.-G., Nam, J.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902626 · Cited by 338
Ten-Year Relative Survival for Epithelial Ovarian Cancer
Baldwin, L. A., Huang, B., Miller, R. W., Tucker, T., Goodrich, S. T., Podzielinski, I., DeSimone, C. P., Ueland, F. R., van Nagell, J. R., & Seamon, L. G. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318264f794 · Cited by 336
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Harter, P., Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., Selle, F., Guyon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103294 · Cited by 335
Self-citationLedermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.015 · Cited by 333
Self-citationMarkers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Self-citationCancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 319
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P. T., & Drapkin, R. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 314
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 311
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 304
Self-citationMonk, B. J., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M. C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00342-9 · Cited by 301
Self-citationMinireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Reconstructing Time-to-event Data from Published Kaplan–Meier Curves
Wei, Y., & Royston, P. (2017) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x1801700402 · Cited by 282
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122113 · Cited by 254
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Self-citationLeung, C. S., Yeung, T.-L., Yip, K.-P., Wong, K.-K., Ho, S. Y., Mangala, L. S., Sood, A. K., Lopez-Berestein, G., Sheng, J., Wong, S. T. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95200 · Cited by 132
VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
Cao, Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.114 · Cited by 109
Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019) · Cancers · doi:10.3390/cancers11050655 · Cited by 102
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.112 · Cited by 98
Self-citationMarth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R., Kurzeder, C., Colombo, N., Vuylsteke, P., Lorusso, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.004 · Cited by 79
Self-citationMieulet, V., Garnier, C., Kieffer, Y., Guilbert, T., Nemati, F., Marangoni, E., Renault, G., Chamming’s, F., Vincent-Salomon, A., & Mechta-Grigoriou, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-83685-0 · Cited by 79
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
The anti-cancer effects of itraconazole in epithelial ovarian cancer
Choi, C. H., Ryu, J.-Y., Cho, Y.-J., Jeon, H.-K., Choi, J.-J., Ylaya, K., Lee, Y.-Y., Kim, T.-J., Chung, J.-Y., Hewitt, S. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06510-7 · Cited by 53
Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0481-y · Cited by 52
Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Prediction of chemo-response in serous ovarian cancer
Gonzalez Bosquet, J., Newtson, A. M., Chung, R. K., Thiel, K. W., Ginader, T., Goodheart, M. J., Leslie, K. K., & Smith, B. J. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0548-9 · Cited by 46
Tewari, K. S., Java, J. J., Gatcliffe, T. A., Bookman, M. A., & Monk, B. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.013 · Cited by 39
Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194693 · Cited by 31
Self-citationWang, Y., Chiou, Y.-S., Chong, Q.-Y., Zhang, M., Rangappa, K. S., Ma, L., Zhu, T., Kumar, A. P., Huang, R. Y.-J., Pandey, V., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00064 · Cited by 20
Buechel, M. E., Enserro, D., Burger, R. A., Brady, M. F., Wade, K., Secord, A. A., Nixon, A. B., Mirniaharikandehei, S., Liu, H., Zheng, B., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.02.032 · Cited by 17
Current First-line Therapy for Ovarian Cancer: A Comprehensive Review
Pierce, S. R., & Clark, L. H. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000613 · Cited by 17
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer
Glassman, D., Kim, M. S., Spradlin, M., Badal, S., Taki, M., Bhattacharya, P., Dutta, P., Kingsley, C. V., Foster, K. I., Animasahun, O., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106020 · Cited by 15
Ivy, S. P., Kunos, C. A., Arnaldez, F. I., & Kohn, E. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1657403 · Cited by 11
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review
Moore, K. N., & Pothuri, B. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000558 · Cited by 9
Metadata
- Authors
- Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., Bois, A. D., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., & Oza, A. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-29
- Volume
- 365
- Issue
- 26
- Pages
- 2484-2496
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113122060
- Cited by
- 2,172
- References
- 22
- FWCI
- 158.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.